In came the pandemic and suddenly being the world leader for a vaccine got kind of interesting

Financier Cathal Friel is a familiar figure in Irish business. Over the years he has worked in finance, oil and gas, technology and media, but it is in his current project, Open Orphan, where he appears to have caught lightning in a bottle.

Open Orphan was only set up in 2017 as a niche pharmaceutical services company.

Two years later, Friel engineered a reverse takeover of stock market Venn Life Sciences – struggling at the time but already established on the Irish stock exchange and able to tap fresh investment.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

How human challenge trials can accelerate vaccine development

Human challenge studies provide more valuable information than animal challenge studies, which produce results that must be extrapolated in order to determine the impact on humans. They also allow for trials on a small participant pool that faces

Open Orphan Plc

Considerations on Manufacturing Challenge Agents webinar

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

Global leader in Human Challenge vaccine development

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

Open Orphan could realise £20 million in first non-core asset IPO

Co-founder Cathal Friel has indicated that a series of spinouts could unlock £750 million for shareholders in the Dublin-based pharma company. Open Orphan, the Dublin-listed pharmaceutical services company run by Cathal Friel, will launch an initial public offering

Open Orphan Plc

Open Orphan considers spinning out assets

Specialist pharmaceutical services clinical research company, Open Orphan, is considering a possible spin-out of certain non-core development intellectual property assets. The company said the potential demerger is at an advanced stage of planning. The assets include HVO-001, a